Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials

Debate exists about the efficacy of β-blockers in myocardial infarction and their required duration of usage in contemporary practice. We conducted a MEDLINE/EMBASE/CENTRAL search for randomized trials evaluating β-blockers in myocardial infarction enrolling at least 100 patients. The primary outcom...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The American journal of medicine Ročník 127; číslo 10; s. 939
Hlavní autoři: Bangalore, Sripal, Makani, Harikrishna, Radford, Martha, Thakur, Kamia, Toklu, Bora, Katz, Stuart D, DiNicolantonio, James J, Devereaux, P J, Alexander, Karen P, Wetterslev, Jorn, Messerli, Franz H
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.10.2014
Témata:
Adrenergic beta-Antagonists - administration & dosage
Adrenergic beta-Antagonists - adverse effects
Adrenergic beta-Antagonists - therapeutic use
Cause of Death
Comorbidity
Databases, Bibliographic
Heart Failure - epidemiology
Humans
Myocardial Infarction - drug therapy
Myocardial Infarction - mortality
Myocardial Infarction - therapy
Myocardial Reperfusion - statistics & numerical data
Randomized Controlled Trials as Topic
Shock, Cardiogenic - epidemiology
Time Factors
Treatment Outcome
Myocardial infarction
β-blockers
Reperfusion
Outcomes
ISSN:1555-7162, 1555-7162
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Debate exists about the efficacy of β-blockers in myocardial infarction and their required duration of usage in contemporary practice. We conducted a MEDLINE/EMBASE/CENTRAL search for randomized trials evaluating β-blockers in myocardial infarction enrolling at least 100 patients. The primary outcome was all-cause mortality. Analysis was performed stratifying trials into reperfusion-era (> 50% undergoing reperfusion or receiving aspirin/statin) or pre-reperfusion-era trials. Sixty trials with 102,003 patients satisfied the inclusion criteria. In the acute myocardial infarction trials, a significant interaction (Pinteraction = .02) was noted such that β-blockers reduced mortality in the pre-reperfusion (incident rate ratio [IRR] 0.86; 95% confidence interval [CI], 0.79-0.94) but not in the reperfusion era (IRR 0.98; 95% CI, 0.92-1.05). In the pre-reperfusion era, β-blockers reduced cardiovascular mortality (IRR 0.87; 95% CI, 0.78-0.98), myocardial infarction (IRR 0.78; 95% CI, 0.62-0.97), and angina (IRR 0.88; 95% CI, 0.82-0.95), with no difference for other outcomes. In the reperfusion era, β-blockers reduced myocardial infarction (IRR 0.72; 95% CI, 0.62-0.83) (number needed to treat to benefit [NNTB] = 209) and angina (IRR 0.80; 95% CI, 0.65-0.98) (NNTB = 26) at the expense of increase in heart failure (IRR 1.10; 95% CI, 1.05-1.16) (number needed to treat to harm [NNTH] = 79), cardiogenic shock (IRR 1.29; 95% CI, 1.18-1.41) (NNTH = 90), and drug discontinuation (IRR 1.64; 95% CI, 1.55-1.73), with no benefit for other outcomes. Benefits for recurrent myocardial infarction and angina in the reperfusion era appeared to be short term (30 days). In contemporary practice of treatment of myocardial infarction, β-blockers have no mortality benefit but reduce recurrent myocardial infarction and angina (short-term) at the expense of increase in heart failure, cardiogenic shock, and drug discontinuation. The guideline authors should reconsider the strength of recommendations for β-blockers post myocardial infarction.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1555-7162
1555-7162
DOI:10.1016/j.amjmed.2014.05.032